Literature DB >> 33763485

Serum Levels of S100A11 and MMP-9 in Patients with Epithelial Ovarian Cancer and Their Clinical Significance.

Wenjing Li1, Zhumei Cui2, Yan Kong1, Xiangyu Liu1, Xiangyu Wang1.   

Abstract

OBJECTIVE: To investigate the serum levels of calgizzarin (S100A11) and matrix metalloproteinase-9 (MMP9) in patients with epithelial ovarian cancer (EOC) and determine their clinical significance.
METHODS: Serum levels of S100A11 and MMP9 were detected in patients with EOC, patients with benign ovarian tumor, and healthy women. The correlation between the two markers and clinicopathological characteristics of ovarian cancer was analysed.
RESULTS: The serum levels of S100A11 and MMP-9 in patients with EOC were higher than those in patients with benign ovarian tumor and in healthy women, and the expression levels of S100A11 and MMP-9 were positively correlated. S100A11 and MMP-9 were correlated with tumor staging, postoperative residual foci, ascites volume, serum CA125 level, chemotherapy response, and lymph node metastasis, while S100A11 and MMP-9 were not associated with the bilevel classification, histological type, age, and degree of differentiation.
CONCLUSION: S100A11 and MMP-9 were both highly expressed in the serum of patients with EOC and were associated with cancer development, invasion, and metastasis. Therefore, they can be used as an important reference maker in the diagnosis and treatment of ovarian cancer.
Copyright © 2021 Wenjing Li et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33763485      PMCID: PMC7952149          DOI: 10.1155/2021/7341247

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


  24 in total

1.  Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells.

Authors:  Jay Shankar; Anat Messenberg; Jackie Chan; T Michael Underhill; Leonard J Foster; Ivan R Nabi
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

2.  Ca2+-binding protein S100A11: a novel diagnostic marker for breast carcinoma.

Authors:  Xiang-Guo Liu; Xiao-Ping Wang; Wan-Feng Li; Shuo Yang; Xin Zhou; Si-Jie Li; Xiang-Jun Li; Dong-Yun Hao; Zhi-Min Fan
Journal:  Oncol Rep       Date:  2010-05       Impact factor: 3.906

3.  NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.

Authors:  Mary B Daly; Robert Pilarski; Matthew B Yurgelun; Michael P Berry; Saundra S Buys; Patricia Dickson; Susan M Domchek; Ahmed Elkhanany; Susan Friedman; Judy E Garber; Michael Goggins; Mollie L Hutton; Seema Khan; Catherine Klein; Wendy Kohlmann; Allison W Kurian; Christine Laronga; Jennifer K Litton; Julie S Mak; Carolyn S Menendez; Sofia D Merajver; Barbara S Norquist; Kenneth Offit; Tuya Pal; Holly J Pederson; Gwen Reiser; Kristen Mahoney Shannon; Kala Visvanathan; Jeffrey N Weitzel; Myra J Wick; Kari B Wisinski; Mary A Dwyer; Susan D Darlow
Journal:  J Natl Compr Canc Netw       Date:  2020-04       Impact factor: 11.908

4.  Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer.

Authors:  Mingzhu Yin; Cong Li; Xia Li; Ge Lou; Bing Miao; Xiaodong Liu; Fanling Meng; Haiyu Zhang; Xiuwei Chen; Meng Sun; Qiu Ling; Rouli Zhou
Journal:  J Surg Oncol       Date:  2011-03-17       Impact factor: 3.454

5.  Clinical significance of ascites in epithelial ovarian cancer.

Authors:  H Huang; Y J Li; C Y Lan; Q D Huang; Y L Feng; Y W Huang; J H Liu
Journal:  Neoplasma       Date:  2013       Impact factor: 2.575

Review 6.  Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.

Authors:  Ignacio Romero; Robert C Bast
Journal:  Endocrinology       Date:  2012-03-13       Impact factor: 4.736

7.  Expression of S100A11 is a Prognostic Factor for Disease-free Survival and Overall Survival in Patients With High-grade Serous Ovarian Cancer.

Authors:  Yanli Li; Jiarong Zhang
Journal:  Appl Immunohistochem Mol Morphol       Date:  2017-02

8.  Cancer of the ovary, fallopian tube, and peritoneum.

Authors:  Jonathan S Berek; Sean T Kehoe; Lalit Kumar; Michael Friedlander
Journal:  Int J Gynaecol Obstet       Date:  2018-10       Impact factor: 3.561

9.  Tudor staphylococcal nuclease drives chemoresistance of non-small cell lung carcinoma cells by regulating S100A11.

Authors:  Anna Zagryazhskaya; Olga Surova; Nadeem S Akbar; Giulia Allavena; Katarina Gyuraszova; Irina B Zborovskaya; Elena M Tchevkina; Boris Zhivotovsky
Journal:  Oncotarget       Date:  2015-05-20

10.  Knockdown of S100A11 expression suppresses ovarian cancer cell growth and invasion.

Authors:  Youqing Liu; Xiaobing Han; Baoan Gao
Journal:  Exp Ther Med       Date:  2015-02-03       Impact factor: 2.447

View more
  1 in total

1.  Association between Rheumatoid Arthritis Disease Activity and Risk of Ovarian Malignancy in Middle-Aged and Elderly Women.

Authors:  Zhaowei Huang; Linlin Tan; Yi Ling; Fangqin Huang; Wukai Ma
Journal:  Biomed Res Int       Date:  2022-05-25       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.